| 摘要 |
Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. |
| 主权项 |
1. A method for the treatment of a condition resulting from a hepatitis C infection, in a host in need thereof, comprising administering an effective amount of a spiro[2.4]heptane of the following structure: wherein: R1 is a natural or non-natural heteroaryl or heterocyclic moiety; R2 is methyl or F; R3 is methyl, F, Cl, N3, or OR7; R4 is OR7, H, methyl, F, Cl, or N3; R5 is H, phosphate, a stabilized phosphate prodrug, phosphoramidate, acyl, alkyl, sulfonate ester, a lipid, a phospholipid, an amino acid, a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R5 is H or mono, di, or tri-phosphate; and, R7 is H, acyl, phosphate, sulfate, amino acid, peptide, or an oxygen-protecting group; or its pharmaceutically acceptable salt; optionally in a pharmaceutically acceptable carrier. |
